News
Health Minister Simeon Brown announced the success of the programme this week, emphasising that it represents a shift toward ...
Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure.
Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
19h
Zacks Investment Research on MSNTempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum
The integration of artificial intelligence (AI) in the cardiovascular space, particularly in electrocardiography (ECG), is reshaping clinical workflows, enabling earlier disease detection and opening ...
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...
6d
GlobalData on MSNFDA grants 510(k) clearance for Tempus AI’s ejection fraction software
The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...
Q: Can you tell me about ejection fractions? My wife’s heart doctor recently told us that her heart is weak, and she has a low ejection fraction. He did not discuss this much, but he has put her ...
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results